The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, according to scientists, we might be in the golden age of biotechnology, making companies such as Summit Therapeutics (SMMT) top investment options right now. Several biotech players, including Summit Therapeutics, have strong drug candidates in clinical-stage trials on the cusp of approval. Shares of Summit Therapeutics have soared over 1,120% in 2024, valuing the company at a market cap of $22.4 billion. Let’s see if it’s too late to buy this breakout biotech stock rig…